-+ 0.00%
-+ 0.00%
-+ 0.00%

Johnson & Johnson said in a study on non-small cell lung cancer, RYBREVANT combined chemotherapy reduced the risk of death by 43%.

Zhitongcaijing·09/14/2026 12:41:35
Listen to the news
Johnson & Johnson said in a study on non-small cell lung cancer, RYBREVANT combined chemotherapy reduced the risk of death by 43%.